Neuberger Berman Group
DNTH icon

Neuberger Berman Group’s Dianthus Therapeutics DNTH Stock Holding History

Neuberger Berman Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Buy
157,574
+98,498
+167% +$8.6M 0.01% 778
2026
Q1 		$4.96M Sell
59,076
-28,706
-33% -$1.66M ﹤0.01% 985
2025
Q4 		$3.62M Buy
+87,782
New +$3.4M ﹤0.01% 1039

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Neuberger Berman Group's DNTH Position: Q2 2026 in Review

Neuberger Berman Group increased its Dianthus Therapeutics (DNTH) stake by 167% in Q2 2026, buying an estimated $8.6M and bringing the position to 157,574 shares worth $15.4M. The position accounts for 0.01% of the portfolio, ranked #778.

Neuberger Berman Group first reported a position in DNTH in Q4 2025 and has held it in 3 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Neuberger Berman Group held 157,574 shares of Dianthus Therapeutics worth $15.4M as of Q2 2026.
  • Neuberger Berman Group bought 98,498 Dianthus Therapeutics shares in Q2 2026, an estimated $8.6M.
  • Dianthus Therapeutics made up 0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #778 holding.
  • Neuberger Berman Group first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.